Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
The study was conducted to describe and compare the plasma pharmacokinetics of NRL972
administered after a standard meal and while fasted in patients with hepatic cirrhosis
(Child-Turcotte-Pugh [CTP] class A-C), NASH, young and elderly healthy males, and young and
elderly healthy females, to assess the effects of liver dysfunction, gender, age and prandial
intestinal hyperaemia on the clearance of NRL972. In addition, the study was to provide
information on the safety and tolerability of repeated intravenous doses of NRL972 in these
populations.